Showing results (51-60 of 183) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJosé Baselga, Javier Cortés, Seock-Ah Im, et al.Pharmacogenomics|January 19, 2022
Evaluation of a longitudinal pharmacogenomics education on pharmacist knowledge in a multicampus healthcare systemAndrew J Lee, Adrian C Hui, Alexander D Walker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapyJennifer A Low, Arlene W Berman, Seth M Steinberg, et al.Cancer Biology & Therapy|December 7, 2007
Circulating biomarkers of bevacizumab activity in patients with breast cancerNeelima Denduluri, Sherry X Yang, Arlene W Berman, et al.Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.Journal of the National Cancer Institute|April 8, 2004
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancerSandra M Swain, John W Wilson, Eleftherios P Mamounas, et al.Breast Cancer Research and Treatment|October 14, 2006
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-upJanice M Walshe, Arlene W Berman, Ujala Vatas, et al.Breast Cancer Research and Treatment|August 29, 2016
Genomic profiling of breast cancer in African-American women using MammaPrintRaquel A Nunes, Lynette Wray, Mihriye Mete, et al.The Oncologist|March 19, 2017
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular FunctionFilipa Lynce, Ana Barac, Ming T Tan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Changes in neurologic function tests may predict neurotoxicity caused by ixabepiloneJames J Lee, Jennifer A Low, Earllaine Croarkin, et al.Pageof 19